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Kawasaki disease (KD) is an acute febrile vasculi-tis of childhood of unknown cause.1 As the coro-navirus disease 2019 (COVID-19) pandemic 
continues, many countries have implemented nonphar-
maceutical interventions (NPIs) to mitigate the spread of 
the virus. In Korea, NPIs such as mandatory mask wear-
ing, school closure, and testing and isolation of symptom-
atic individuals were implemented in February 2020, with 
good compliance.2 On-site school reopening was post-
poned until May 20, 2020, and schools were reopened 
gradually until June 6, maintaining strict policies such as 
physical distancing and restrictions on private education 
and group activities.2 This nationwide intervention pro-
vided a unique opportunity for us to investigate the col-
lateral effect of NPIs on the incidence of other diseases. 
We aimed to investigate whether NPIs were associated 
with a change in KD incidence in Korea, the country with 
the second-highest KD incidence rate worldwide.
In this retrospective, ecologic study, data on all KD cases 
among children 0 to 19 years of age from January 2010 
to September 2020 were collected using the National 
Health Insurance Service database. The NPI period was 
defined as February through September 2020. The KD 
incidence rate in the NPI period was compared with the 
annual mean incidence rate during the same months in 
the pre-NPI period and with the incidence rate predicted 
by the autoregressive integrated moving average model. 
KD was defined as a case where the International 
Classification of Diseases–10 diagnostic code for KD 
(M30.3) and the prescription code for intravenous im-
munoglobulin (IVIg) were claimed together. IVIg-resistant 
KD was defined as recrudescent or persistent fever 24 
to 48 hours after the first IVIg infusion, requiring an IVIg 
prescription nonconsecutively for at least 3 days. These 
data are licensed for this analysis only, and the institu-
tional review board approved the study.
A total of 53 424 cases of KD were identified; among 
these, 83% occurred in children <5 years of age, and 
17% were resistant to IVIg. In the pre-NPI period, the 
annual mean incidence was 48.1 per 100 000 persons 
and the monthly mean incidence was 4.1/100 000 
(Figure [A]). After NPI implementation, KD incidence 
declined sharply; from April onward, it plateaued (Figure 
[B]). KD incidence is typically seasonal, with a minor peak 
in the late spring and summer and a larger one in the 
winter; however, this seasonal pattern was absent in the 
NPI period. When considering the months from Febru-
ary to September, the incidence in the NPI period was 
18.8/100 000, corresponding to 60% of the mean inci-
dence (31.5/100 000) in the pre-NPI period (P=0.085) 
and 58% of the predicted incidence (32.2/100 000 [95% 
CI, 46.6–77.9%]). The incidence in children between 0 
and 4 years of age, the group with the highest incidence 
rate, was 80.0/100 000, significantly lower than the 
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mean incidence in the pre-NPI period (123.0/100 000; 
P=0.003) and the predicted incidence (123.3/100 000 
[95% CI, 51.9–86.7%]; Figure [C]). In the 5 to 9 years of 
age group, the incidence (10.6/100 000) was also sig-
nificantly lower than the mean incidence (23.8/100 000) 
in the pre-NPI period (P=0.04) and the predicted inci-
dence (24.7/100 000 [95% CI, 30.9–70.6%]; Figure 
[D]). However, there was no difference in the incidence 
before and after NPI implementation in the 10 to 19 
years of age group, the group with the lowest incidence 
(Figure [E]).
The incidence of IVIg-resistant KD had been increas-
ing since 2018 in the pre-NPI period (Figure [A]), 
whereas the overall KD incidence did not change signifi-
cantly (post/pre-NPI slope coefficient=0.04, P<0.0001). 
There was no significant change in the incidence of IVIg-
resistant KD during the NPI period (6.8/100 000) com-
pared with the annual mean of the previous 10 years 
(5.1/100 000; P>0.99).
The reasons for the association of NPI-related fac-
tors and KD incidence decrease are unclear. A reduction 
in respiratory viral infections and climate change, which 
have been cited as potential external triggers, were also 
associated with our findings.2–4 The incidence of KD-
like diseases such as adenovirus infection and measles, 
which cause febrile rashes that can mimic KD, decreased 
after implementation of NPIs; this association may have 
created a bias.2 However, the proportion of IVIg-resistant 
KD, a severe form of KD, did not change in 2020 com-
pared with that in 2019 (37.7% and 36.2%, respectively; 
P=0.28). This finding suggests that the decrease of KD-
like diseases, generally milder than KD, had little effect 
on the overall decrease in the incidence of KD. Never-
theless, the KD incidence rate in Korea (80/100 000 
children <5 years of age) is 3 to 16 times higher than 
that in Western countries (5 to 25/100 000 children <5 
years of age), even after NPI implementation.1,5 This dif-
ference suggests that other variables, such as genetic 
and ethnic factors, are important in the pathogenesis of 
KD, regardless of the effect of NPIs.5
This nationwide study reveals that the KD incidence 
decreased significantly after the implementation of NPIs 
Figure. Kawasaki disease (KD) incidence in Korea.
A, Yearly incidence of KD from 2010 to 2020. The red line denotes the age-specific incidence of KD, and the blue line denotes the age-specific 
incidence of intravenous immunoglobulin (IVIg)–resistant KD. The dotted line represents February 2020, when nonpharmaceutical interventions 
(NPIs) were implemented in Korea owing to coronavirus disease 2019 (COVID-19). B through E, Monthly incidence of KD and incidence predicted 
by an autoregressive integrated moving average model. The thick red line denotes the observed incidence during the NPI period, the thick blue line 
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in Korea. Further long-term research is needed to deter-
mine whether the decrease in incidence of KD is solely 
attributable to the effects of NPIs.
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